Evaluation of high-throughput sequencing for replacing the conventional adventitious virus detection assays used for biologics
npj Vaccines · 23.12.2025 · 11 (1)
DOI: 10.1038/s41541-025-01351-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift npj Vaccines, online erschienen am 23.12.2025. Verfasst von Pei-Ju Chin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, …. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Innovation in Manufacturing Biopharmaceuticals/Gates Foundation.
Abstract (Originalsprache)
High-throughput sequencing (HTS) can detect known and novel adventitious viruses in biological materials that might be missed by the conventional in vitro and in vivo assays. We compared HTS with the conventional assays using the same sample preparation of CHO cell harvest spiked with human respiratory syncytial virus (RSV) and mammalian orthoreovirus (Reo1). The viruses were selected with the expectation that one would produce a positive result in each test. The study results indicated both RSV and Reo1 were detected by HTS and in vitro assays, albeit with inter-assay and intra-lab differences in sensitivity of virus detection, and only Reo1 was detected by the in vivo assays. The results support using HTS to replace the in vivo assays. Additionally, based on capabilities of HTS for non-targeted virus detection, it may supplement or replace the in vitro assays. The study further highlighted that the analytical sensitivity of HTS can be improved.
Autor:innen und Institutionen
- Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
- Office of the Director, Facility of Biotechnology Resources, CBER USA FDA, Silver Spring, MD, USA.
- Millipore Sigma, Rockville, MD, USA.
- GSK, Wavre, Wavre, Belgium.
- EMD Serono RBM S.p.A. Istituto di Ricerche Biomediche A. Marxer, Via Ribes 1 10010 Colleretto Giacosa, Italy, an affiliate of Merck KGaA, Darmstadt, Germany.
- Akkodis Belgium c/o GSK, Evere, 1140, Belgium.
Förderung
- National Institute for Innovation in Manufacturing Biopharmaceuticals/Gates Foundation
Zitieren
APA
Chin, P. J., Tsou, J. H., Armstrong, A., Deneyer, N., Zanda, V., Ayama-Canden, S., Colinet, A. S., Fuentes, S. M., Korokhov, N., Lambert, C., Lavorgna, A., Noll, M., Olgiati, S., Protz, M., Shaid, S., Sohrabi, A., Whiteman, M., & Khan, A. S. (2025). Evaluation of high-throughput sequencing for replacing the conventional adventitious virus detection assays used for biologics. npj Vaccines, 11(1). https://doi.org/10.1038/s41541-025-01351-2
Vancouver
Chin PJ, Tsou JH, Armstrong A, Deneyer N, Zanda V, Ayama-Canden S, et al. Evaluation of high-throughput sequencing for replacing the conventional adventitious virus detection assays used for biologics. npj Vaccines. 2025;11(1). doi:10.1038/s41541-025-01351-2
BibTeX
@article{Chin2025,
author = {Chin, Pei-Ju and Tsou, Jen-Hui and Armstrong, Alison and Deneyer, Noémie and Zanda, Valeria and Ayama-Canden, Sophie and Colinet, Anne-Sophie and Fuentes, Sandra M and Korokhov, Nikolay and Lambert, Christophe and Lavorgna, Alfonso and Noll, Manuel and Olgiati, Simone and Protz, Michel and Shaid, Shahjahan and Sohrabi, Afshin and Whiteman, Mary and Khan, Arifa S},
title = {Evaluation of high-throughput sequencing for replacing the conventional adventitious virus detection assays used for biologics},
journal = {npj Vaccines},
year = {2025},
volume = {11},
number = {1},
doi = {10.1038/s41541-025-01351-2}
}
EUVIMED